WuXi Biologics

Headquarters: Wuxi, China

Employees: 9,864

CEO: Dr. Zhisheng Chen

show_chart HKEX: 2269 -0.71%

Market Cap

HK$271.11 Billion

HKD as of Jan. 1, 2023

US$34.54 Billion

history Market Cap History

WuXi Biologics market capitalization over time

Evolution of WuXi Biologics market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of WuXi Biologics

Detailed Description

WuXi Biologics (Cayman) Inc., an open-access biologics technology platform company, provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sales of medicals; vaccine CDMO and related business; and material supplier activities. It has strategic partnerships with Almirall, S.A.; Vir Biotechnology, Inc.; Aravive, Inc.; Tubulis GmbH; Arcus Biosciences, Inc.; AC Immune SA; and AB2 Bio Ltd. The company was incorporated in 2014 and is headquartered in Wuxi, China. WuXi Biologics (Cayman) Inc. is a subsidiary of WuXi Biologics Holdings Limited.

Stocks & Indices

WuXi Biologics has the following listings and related stock indices.

Stock: HKEX: 2269

Stock: FSX: 1FW1




No. 108, Meiliang Road

Mashan Binhu District

Wuxi, 214092